Biogen Inc. (BIIB)

Over the past six months, Biogen's stock (BIIB) has increased significantly, with a 40.33% price return. As of January 9, 2026, the stock was up 5.67% over the past 30 days and 26.07% over the past 12 months, reaching a new 52-week high near $185.79 on January 7, 2026. Key events include Q3 2025 earnings beat, mixed analyst ratings and price target revisions, successful commercialization of new products, competitive pressures in the MS portfolio, pipeline prioritization, and the acquisition of Alcyone Therapeutics.

Specific demand seasonality data for Biogen Inc.'s products is not readily available. However, financial reports indicate that product mix and the timing of shipments can influence quarterly revenues. Planned plant maintenance activities can also lead to minimal contract manufacturing revenue in certain quarters.

Biogen Inc. is a multinational biotechnology company focused on therapies for neurological and neurodegenerative diseases, including multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and rare diseases. Major products include MS treatments like Tecfidera, Vumerity, AVONEX, Plegridy, and Tysabri, which collectively represented 45% of 2024 revenues. Other key products are Nusinersen (Spinraza) for SMA, Omaveloxolone (Skyclarys) for Friedreich's Ataxia, Tofersen (Qalsody) for ALS, Leqembi for Alzheimer's disease, Zurzuvae for postpartum depression, Fumaderm for severe plaque psoriasis, and biosimilars. The company also generates revenue from collaboration agreements, such as its CD20 collaboration with Roche.

Biogen has a global presence with operations in North America, Europe, Japan, and other international markets. Its global headquarters are in Cambridge, Massachusetts, and its international headquarters are in Baar, Switzerland. The company has a direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. Major manufacturing facilities are located in North Carolina, U.S., and Solothurn, Switzerland. The U.S. is home to its main innovation hubs, with R&D teams primarily in Cambridge, MA, and a West Coast Hub in South San Francisco, CA. Biogen operates in five regions: U.S., Europe, Germany, Asia, and Other.

In the past year, Biogen's brand reputation has been influenced by skepticism on Alzheimer's drugs and its overall pipeline, competitive dynamics in the multiple sclerosis franchise, recognition for its rare disease portfolio, and pipeline prioritization. Investors have shown skepticism regarding Biogen's Alzheimer's drugs and its overall pipeline. The declining multiple sclerosis franchise due to competitive pressures from newer drugs and loss of exclusivity events has impacted the company's business. Biogen has been recognized for its significant prowess in commercially executing on its rare disease portfolio. The company is prioritizing high-conviction assets with potential for significant growth, aiming to drive a new era of growth.

Biogen's stock ownership is primarily held by institutional investors, who own approximately 84.53% of the company's stock. Individual investors and public companies hold about 15.29%, while insiders own approximately 0.18%. Major institutional owners include Vanguard Group Inc., Primecap Management Co/ca/, BlackRock, Inc., State Street Corp, Wellington Management Group Llp, Geode Capital Management, Llc, Point72 Asset Management, L.P., Norges Bank Investment Management (NBIM), and Invesco Capital Management LLC.